Back to results
US 2026/0132180 A1Published application
Oncoselective therapy
AssigneeKernal Biologics, Inc.
InventorsBurak YILMAZ, Cafer OZDEMIR, Yusuf ERKUL, Thomas ADDISON, Isaak MUELLER, Kelly BROCK, Sadik YILDIZ, William Max ALEXANDER, Manfred KRAUS, Yulia RYBAKOVA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for treatment of diseases or conditions.
Claims31
An engineered polynucleotide comprising:
- at least one oncoselective sequence;
- and
- a coding sequence encoding an engineered therapeutic, wherein the at least one oncoselective sequence comprises a nucleic acid sequence that is:
- at least 75% identical to any one of SEQ ID NOs:
- 1-97 or 101-146.
2 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-50. (canceled)
(canceled)
-61. (canceled)
-73. (canceled)
A method for treating a disease or condition in a subject, comprising administering to the subject an engineered polynucleotide, said engineered polynucleotide comprises at least one oncoselective sequence;
- and a coding sequence encoding an engineered therapeutic, wherein the at least one oncoselective sequence comprises a nucleic acid sequence that is:
- at least 75% identical to any one of SEQ ID NOs:
- 1-97 or 101-146.
-101. (canceled)
Dependencies are inferred from the claim text.